The stock will trade on pipeline catalysts rather than quarterly financials. Key binary events to watch: ZYNQUISTA NDA resubmission (Q4 2026) and SONATA-HCM topline data (Q1 2027). The $190.6M cash position funds operations through these milestones. Monitor for potential $10M milestone payment from Novo Nordisk later this year.
Price Chart
Executive Summary
Lexicon Pharmaceuticals reported Q2 2026 total revenue of $0.7M, a sharp decline from $28.9M in Q2 2025 which included a $27.6M licensing milestone from Novo Nordisk. Net loss widened to $31.8M ($0.07/share) vs net income of $3.3M ($0.01/share) a year ago. The quarter's focus was on pipeline execution: SONATA-HCM enrollment completed on time (topline Q1 2027), ZYNQUISTA NDA resubmission expected Q4 2026, and cash position of $190.6M provides runway through key catalysts.
Key Financial Metrics
Key Facts
- Total revenue Q2 2026: $0.7M vs $28.9M in Q2 2025 (prior year included $27.6M Novo Nordisk milestone)
- Net loss Q2 2026: $31.8M ($0.07/share) vs net income of $3.3M ($0.01/share) in Q2 2025
- SONATA-HCM Phase 3 enrollment completed, substantially exceeding 500-patient target; topline data expected Q1 2027
- ZYNQUISTA NDA resubmission for type 1 diabetes anticipated in Q4 2026
- Cash and investments: $190.6M as of June 30, 2026, up from $125.2M at Dec 31, 2025
- R&D expenses increased to $17.4M from $15.7M, driven by SONATA-HCM trial costs
- Loss on early extinguishment of debt: $4.3M in Q2 2026
Financial Impact
Revenue declined 97.6% YoY due to absence of prior-year licensing milestone; net loss of $31.8M vs prior-year net income of $3.3M; cash burn of ~$35M in H1 2026
Risk Factors
- ZYNQUISTA NDA resubmission may face delays or additional FDA data requirements
- SONATA-HCM topline results could miss efficacy endpoints
- Cash burn rate may require additional financing before reaching profitability
- INPEFA commercial revenue remains minimal at $0.7M/quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062822-26-000112 |
| Document: lxrx-20260806.htm | 0001062822-26-000112 |
| Document: 0001062822-26-000112-index-headers.html | 0001062822-26-000112 |
| Document: 0001062822-26-000112-index.html | 0001062822-26-000112 |
| Document: 0001062822-26-000112.txt | 0001062822-26-000112 |
| 8-K Data (Synthetic) | 0001062822-26-000112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Aug 6, 2026 8w ago | Press Release | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.92 $2.22 | ▼ −15.63% | ▼ −13.85% | $1.82 (+5.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.89 $2.25 | ▲ +19.05% | ▲ +17.16% | $1.82 (−3.70%) |
May 6, 2026 21w ago | 8-K | $1.68 $1.85 | ▲ +10.12% | ▲ +6.98% | $1.82 (+8.33%) |
Apr 30, 2026 22w ago | 8-K | $1.63 $2.07 | ▼ −26.99% | ▼ −21.71% | $1.82 (−11.66%) |
Apr 30, 2026 22w ago | Press Release | $1.61 $2.21 | ▲ +37.27% | ▲ +32.30% | $1.82 (+13.04%) |
Mar 24, 2026 27w ago | Press Release | $1.72 $1.82 | ▲ +5.81% | ▼ −3.09% | $1.82 (+5.81%) |
Mar 23, 2026 27w ago | Press Release | $1.64 $1.83 | ▲ +11.59% | ▲ +4.17% | $1.82 (+10.98%) |
Mar 16, 2026 28w ago | DEFA14A | $1.62 $1.86 | ▲ +14.81% | ▲ +10.51% | $1.82 (+12.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access